The French Gut: Characterization of Gut Microbiota Profiles in France

Status Recruiting

Clinical Trial Summary

" The French Gut " is a national contribution aiming to collect 100,000 faecal samples and associated nutritional and clinical data by 2027. Le French Gut is initiated by MetaGenoPolis-INRAE, supported by INRAE with Prof. R. Benamouzig, (AP-HP) as principal investigator of the project. The main goal of this national trial is a better understanding of the observed heterogeneity between gut microbiome of healthy subjects, its connections with the diet and lifestyle, but also changes in gut microbiota associated with diseases (diabetes, obesity, allergies, cancer, Parkinson, Alzheimer…).

Clinical Trial Description

At the 14th International Conference on Genomics (ICG-14), scientists from China, Sweden, Denmark, France and Latvia launched The Million Microbiome of Humans Project (MMHP) and agreed to collaborate on a large-scale microbial metagenomic project. The overarching goal is to build the world's largest database of human microbiota with one million microbial samples from the intestines, mouth, skin and reproductive system. Therefore, making it possible to characterize the microbiota of people according to age, gender, height, weight, etc. As a founding member of the MMHP, INRAE will bring the French national contribution: 100 000 faecal samples and associated nutritional and clinical data from France, by 2027, through Le French Gut project. Initiated by the MGP research unit, Le French Gut is led by INRAE and the AP-HP (Public Assistance-Hospitals of Paris), with the support and collaboration of a consortium of members from medical, scientific and industrial sectors. In order to be a participant of the project, volunteers will need to fill out an online questionnaire with 60 questions about their lifestyle, their dietary habits and their medical background. The second requirement is the stool sampling, at home. Main scientific targets of this project are the following: - Build a map of the intestinal microbiota in France, reflecting differences in term of gut microbiome through ages, gender, regions of life, diets, habits and medical status; - Describe and better understand the heterogeneity between gut microbiota of healthy subjects and investigate the connection between this heterogeneity with diet and habits. - Describe the variations of the intestinal microbiota associated with the presence and development of certain diseases (chronic diseases, neurodevelopmental disorders, neurodegenerative diseases,…) ;

Study Design

Related Conditions & MeSH terms

General Population

Clinical Trial Details

NCT number	NCT05758961
Study type	Observational
Source	Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Contact	Robert BENAMOUZIG, Pr
Phone	00148955434
Email	robert.benamouzig@aphp.fr
Status	Recruiting
Phase
Start date	September 15, 2022
Completion date	September 15, 2042

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06017687` - Data Collection and Evaluation of OptiBP Under Investigational Use	N/A
Not yet recruiting	`NCT06294080` - Effects of Dance and Tai Chi on Balance and Wellbeing on Healthy Adults	N/A
Completed	`NCT01932827` - Attidutes and Understanding of Oat Fibre Claims on Food Labels	N/A
Completed	`NCT01932840` - Attitudes and Understanding of Plant Sterol Claims on Food Labels	N/A
Completed	`NCT05530720` - Acceptance of Complementary Medicine in Germany
Recruiting	`NCT06166810` - Capture of Healthy Gut Bacteria Associated to High Fiber Diet
Completed	`NCT04384419` - Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)
Recruiting	`NCT05328856` - Effects of Vital Shower on Quality of Life, Immune Function, Cardiovascular Regulation and Well-being	N/A
Completed	`NCT05338372` - Effects of Forest Therapy on Physical and Psychological Parameters in the General Population	N/A
Recruiting	`NCT05336604` - STUDY OF THE COVID-19 EPIDEMIC AND SOCIO-ECONOMIC LIVING CONDITIONS IN FRANCE
Recruiting	`NCT05400824` - Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)
Active, not recruiting	`NCT03257449` - Effect of Viscous Soluble Fibres on Body Weight	N/A
Completed	`NCT03024853` - Efficacy of Different Versions of the Best Possible Self Intervention	N/A
Completed	`NCT05403398` - BSCU1 and Immune Function	N/A
Completed	`NCT02685241` - Monitoring of Biomarkers by Portable Breath Gas Sensors: an Exploratory Study
Active, not recruiting	`NCT04386135` - DESVELA. Personal Skills as Determinants of Morbidity, Lifestyles, Quality of Life, Use of Services and Mortality.
Completed	`NCT04288908` - Trait Injustice, Social Exclusion, and Anger	N/A
Not yet recruiting	`NCT05174962` - National Stigma Survey About Mental Illness, Intellectual Disability and Homelessness in Spain
Completed	`NCT01260792` - Children and Parents With ADHD and Related Disorders	N/A
Completed	`NCT04551638` - Virtual-self Identity Construal in Online Video Games: A Repertory Grid Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.